TG Therapeutics Reports Stable or Improved Disability in 89% of Evaluable Patients in Phase 1 Azer-cel MS Trial at Day 90
Bitget2026/10/23 14:55- TG Therapeutics announced preliminary Phase 1 results for azer-cel in progressive multiple sclerosis, already presented at MSToronto2026, held October 21-23.
- Most evaluable patients had stable or improved disability despite prior progression on high-efficacy therapies, including anti-CD20 treatments.
- The 26-participant study showed no dose-limiting toxicities or high-grade CAR T-cell-related toxicities.
- Findings remain limited by the small study population and short follow-up; dose escalation and longer-term follow-up are ongoing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Moderna shares rise after raising annual revenue growth forecast
US November Michigan consumer sentiment exceeds expectations, rises to three-month high; independent voters' confidence increases, inflation expectations improve
The preliminary November Consumer Sentiment Index from the University of Michigan rose to 51 from 48 in October, surpassing the market's expectation of 48. This improvement was mainly concentrated among independent voters, whose consumer confidence reached a one-year high. About 57% of respondents proactively mentioned that high prices are affecting their standard of living, the highest percentage since May. Consumers expect prices to rise by 4.3% over the next year, the lowest level in three months.
Crypto prices
More
